Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2019 Publisher: LEO Pharma Ltd, Auckland, New Zealand, Ph: 0800 497 456
Fucicort is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.
A small quantity should be applied to the affected area twice daily until a satisfactory response is obtained. A single treatment course should not normally exceed 2 weeks.
In the more resistant lesions the effect of Fucicort cream can be enhanced by occlusion with polyethylene film. Overnight occlusion is usually adequate.
For topically applied fusidic acid, no information concerning potential symptoms and signs due to overdose administration is available. Cushing’s syndrome and adrenocortical insufficiency may develop following topical application of corticosteroids in large amounts and for more than three weeks.
Systemic consequences of an overdose of the active substances after accidental oral intake are unlikely to occur. The amount of fusidic acid in one tube of Fucicort does not exceed the oral daily dose of systemic treatment. A single oral overdose of corticosteroids is rarely a clinical problem.
For advice on the management of overdose please contact the National Poisons Centre 0800 POISON (0800 764 766).
3 years.
Store at or below 30°C.
15 g.
Any unused medicine or waste material should be disposed of in accordance with local
legislation.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
